Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
PHGE
$4.52
$
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Next Earnings
2026-02-25
Beta
1.662
Average Volume
Market Cap
Last Dividend
CIK
0001739174
ISIN
US09090D5095
CUSIP
09090D103
CEO
Jonathan Eitan Solomon
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
52
IPO Date
2019-03-13
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| BiomX Issues Statement Regarding Recent Common Stock Trading Activity | NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. | GlobeNewsWire | 2026-01-27 13:41:00 |
| All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy | BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | Zacks Investment Research | 2025-12-29 13:01:02 |
| BiomX Announces $3.0 Million Private Placement | Proceeds to Support the Company's Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives Proceeds to Support the Company's Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives | GlobeNewsWire | 2025-12-29 08:00:00 |
| BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review | Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). | Globe News Wire | 2025-12-08 07:30:00 |
| BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review | BiomX Inc. (NYSE: PHGE) on Tuesday announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the company's Phase 2b trial of BX004 in cystic fibrosis patients. | Benzinga | 2025-11-26 13:23:04 |
| BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis | The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial | GlobeNewsWire | 2025-11-25 16:40:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 10-K | 2026-02-19 | 2026-02-19 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| EFFECT | 2026-02-13 | 2026-02-17 | View Filing |
| 424B3 | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 8-K | 2026-02-13 | 2026-02-13 | View Filing |
| DEF 14A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13D/A | 2026-02-11 | 2026-02-11 | View Filing |
| 8-K | 2026-02-10 | 2026-02-10 | View Filing |
| S-3 | 2026-02-09 | 2026-02-09 | View Filing |
| PRE 14A | 2026-02-03 | 2026-02-03 | View Filing |
| SC 13G/A | 2026-01-29 | 2026-01-29 | View Filing |
| SC 13D | 2026-01-26 | 2026-01-26 | View Filing |
| D | 2026-01-20 | 2026-01-20 | View Filing |
| 3 | 2026-01-16 | 2026-01-16 | View Filing |
| 8-K | 2026-01-14 | 2026-01-14 | View Filing |
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-12-11 | 2025-12-11 | View Filing |
| 8-K | 2025-12-08 | 2025-12-08 | View Filing |
| 8-K | 2025-11-25 | 2025-11-25 | View Filing |
| 8-K | 2025-11-17 | 2025-11-17 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| ARS | 2025-08-28 | 2025-08-28 | View Filing |
| DEFA14A | 2025-08-28 | 2025-08-28 | View Filing |
| DEF 14A | 2025-08-28 | 2025-08-28 | View Filing |
| 8-K | 2025-08-19 | 2025-08-19 | View Filing |
| PRE 14A | 2025-08-15 | 2025-08-15 | View Filing |
| 424B5 | 2025-08-13 | 2025-08-13 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| SC 13G/A | 2025-08-07 | 2025-08-07 | View Filing |
| SC 13G | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-07-30 | 2025-07-30 | View Filing |
| 8-K | 2025-07-08 | 2025-07-08 | View Filing |
| SC 13D/A | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-09 | 2025-06-09 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-08 | 2025-05-08 | View Filing |
| 424B3 | 2025-04-24 | 2025-04-24 | View Filing |
| EFFECT | 2025-04-24 | 2025-04-24 | View Filing |
| 4 | 2025-04-23 | 2025-04-23 | View Filing |
| 8-K | 2025-04-23 | 2025-04-23 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4/A | 2025-04-21 | 2025-04-21 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| DEFA14A | 2025-04-17 | 2025-04-17 | View Filing |
| S-1 | 2025-04-11 | 2025-04-11 | View Filing |
| DEFA14A | 2025-04-01 | 2025-04-01 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| DEF 14A | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| PRE 14A | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-05 | 2025-03-05 | View Filing |
| SC 13G/A | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 5 | 2025-03-04 | 2025-03-04 | View Filing |
| SC 13D/A | 2025-03-03 | 2025-03-03 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 8-K | 2025-02-27 | 2025-02-27 | View Filing |
| 424B5 | 2025-02-27 | 2025-02-27 | View Filing |
| 424B3 | 2025-02-27 | 2025-02-27 | View Filing |
| 424B5 | 2025-02-24 | 2025-02-24 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2024-12-16 | 2024-12-16 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-13 | 2024-11-13 | View Filing |
| SC 13G/A | 2024-11-13 | 2024-11-13 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| 15-12G | 2024-10-31 | 2024-10-31 | View Filing |
| SC 13G/A | 2024-10-28 | 2024-10-28 | View Filing |
| 25-NSE | 2024-10-25 | 2024-10-25 | View Filing |
| 8-K | 2024-10-15 | 2024-10-15 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|